The wonderland of neuronal nicotinic acetylcholine receptors

Daniel Bertrand, Alvin V Terry

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Nearly 30 years of experimental evidence supports the argument that ligands of nicotinic acetylcholine receptors (nAChRs) have potential as therapeutic agents. However, as in the famous Lewis Carroll novel “Alice in Wonderland”, there have been many unexpected adventures along the pathway of development, and few nAChR ligands have been approved for any clinical condition to date with the exception of nicotine dependence. The recent failures of nAChR ligands in AD and schizophrenia clinical trials have reduced enthusiasm for this therapeutic strategy and many pharmaceutical companies have now abandoned this field of research. As with other clinical failures, multiple questions arise as to the basis for the failure. More generic questions focus on a potential translational gap between the animal models used and the human clinical condition they are meant to simulate, or the clinical trial mindset that large Ns have to be achieved for statistical power (often requiring multiple trial sites) as opposed to smaller patient cohorts at limited sites where conditions can be better controlled and replicated. More specific to the nAChR field are questions about subtype selectivity, dose selection, whether an agonist, antagonist, or allosteric modulator strategy is best, etc. The purpose of this review is to discuss each of these questions, but also to provide a brief overview of the remarkable progress that has been made over the last three decades in our understanding of this unique ligand-gated ion channel and how this new knowledge may help us improve drug development successes in the future.

Original languageEnglish (US)
Pages (from-to)214-225
Number of pages12
JournalBiochemical Pharmacology
Volume151
DOIs
StatePublished - May 1 2018

Fingerprint

Nicotinic Receptors
Ligands
Clinical Trials
Ligand-Gated Ion Channels
Tobacco Use Disorder
Nicotine
Pharmaceutical Preparations
Modulators
Schizophrenia
Animals
Animal Models
Therapeutics
Research
Industry

Keywords

  • Alzheimer's disease
  • Attention deficit hyperactivity disorder
  • Drug discovery
  • Mild cognitive impairment
  • Nicotinic acetylcholine receptor
  • Schizophrenia

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

The wonderland of neuronal nicotinic acetylcholine receptors. / Bertrand, Daniel; Terry, Alvin V.

In: Biochemical Pharmacology, Vol. 151, 01.05.2018, p. 214-225.

Research output: Contribution to journalReview article

@article{5cfb6c9a66f34e89b421e4856124a3ff,
title = "The wonderland of neuronal nicotinic acetylcholine receptors",
abstract = "Nearly 30 years of experimental evidence supports the argument that ligands of nicotinic acetylcholine receptors (nAChRs) have potential as therapeutic agents. However, as in the famous Lewis Carroll novel “Alice in Wonderland”, there have been many unexpected adventures along the pathway of development, and few nAChR ligands have been approved for any clinical condition to date with the exception of nicotine dependence. The recent failures of nAChR ligands in AD and schizophrenia clinical trials have reduced enthusiasm for this therapeutic strategy and many pharmaceutical companies have now abandoned this field of research. As with other clinical failures, multiple questions arise as to the basis for the failure. More generic questions focus on a potential translational gap between the animal models used and the human clinical condition they are meant to simulate, or the clinical trial mindset that large Ns have to be achieved for statistical power (often requiring multiple trial sites) as opposed to smaller patient cohorts at limited sites where conditions can be better controlled and replicated. More specific to the nAChR field are questions about subtype selectivity, dose selection, whether an agonist, antagonist, or allosteric modulator strategy is best, etc. The purpose of this review is to discuss each of these questions, but also to provide a brief overview of the remarkable progress that has been made over the last three decades in our understanding of this unique ligand-gated ion channel and how this new knowledge may help us improve drug development successes in the future.",
keywords = "Alzheimer's disease, Attention deficit hyperactivity disorder, Drug discovery, Mild cognitive impairment, Nicotinic acetylcholine receptor, Schizophrenia",
author = "Daniel Bertrand and Terry, {Alvin V}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.bcp.2017.12.008",
language = "English (US)",
volume = "151",
pages = "214--225",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The wonderland of neuronal nicotinic acetylcholine receptors

AU - Bertrand, Daniel

AU - Terry, Alvin V

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Nearly 30 years of experimental evidence supports the argument that ligands of nicotinic acetylcholine receptors (nAChRs) have potential as therapeutic agents. However, as in the famous Lewis Carroll novel “Alice in Wonderland”, there have been many unexpected adventures along the pathway of development, and few nAChR ligands have been approved for any clinical condition to date with the exception of nicotine dependence. The recent failures of nAChR ligands in AD and schizophrenia clinical trials have reduced enthusiasm for this therapeutic strategy and many pharmaceutical companies have now abandoned this field of research. As with other clinical failures, multiple questions arise as to the basis for the failure. More generic questions focus on a potential translational gap between the animal models used and the human clinical condition they are meant to simulate, or the clinical trial mindset that large Ns have to be achieved for statistical power (often requiring multiple trial sites) as opposed to smaller patient cohorts at limited sites where conditions can be better controlled and replicated. More specific to the nAChR field are questions about subtype selectivity, dose selection, whether an agonist, antagonist, or allosteric modulator strategy is best, etc. The purpose of this review is to discuss each of these questions, but also to provide a brief overview of the remarkable progress that has been made over the last three decades in our understanding of this unique ligand-gated ion channel and how this new knowledge may help us improve drug development successes in the future.

AB - Nearly 30 years of experimental evidence supports the argument that ligands of nicotinic acetylcholine receptors (nAChRs) have potential as therapeutic agents. However, as in the famous Lewis Carroll novel “Alice in Wonderland”, there have been many unexpected adventures along the pathway of development, and few nAChR ligands have been approved for any clinical condition to date with the exception of nicotine dependence. The recent failures of nAChR ligands in AD and schizophrenia clinical trials have reduced enthusiasm for this therapeutic strategy and many pharmaceutical companies have now abandoned this field of research. As with other clinical failures, multiple questions arise as to the basis for the failure. More generic questions focus on a potential translational gap between the animal models used and the human clinical condition they are meant to simulate, or the clinical trial mindset that large Ns have to be achieved for statistical power (often requiring multiple trial sites) as opposed to smaller patient cohorts at limited sites where conditions can be better controlled and replicated. More specific to the nAChR field are questions about subtype selectivity, dose selection, whether an agonist, antagonist, or allosteric modulator strategy is best, etc. The purpose of this review is to discuss each of these questions, but also to provide a brief overview of the remarkable progress that has been made over the last three decades in our understanding of this unique ligand-gated ion channel and how this new knowledge may help us improve drug development successes in the future.

KW - Alzheimer's disease

KW - Attention deficit hyperactivity disorder

KW - Drug discovery

KW - Mild cognitive impairment

KW - Nicotinic acetylcholine receptor

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85038962209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038962209&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2017.12.008

DO - 10.1016/j.bcp.2017.12.008

M3 - Review article

C2 - 29248596

AN - SCOPUS:85038962209

VL - 151

SP - 214

EP - 225

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -